Hispanic Patients with FL Had Lower All-Cause Mortality

Among patients from Montefiore Medical Center in the Bronx, N.Y., Hispanic patients diagnosed with follicular lymphoma (FL) had lower all-cause mortality compared with non-Hispanic Whites, but no differences were found for chronic lymphocytic leukemia (CLL).

“We previously reported lower all-cause mortality among Hispanics with diffuse large B-cell lymphoma (DLBCL) compared to NHWs at Montefiore Medical Center (MMC) in the Bronx, NY,” the researchers wrote. “MMC is uniquely situated for studying racial/ethnic differences in health outcomes given its largely underserved, racially and ethnically diverse urban patient population.”

Researchers with the study looked at patients with incident FL or CLL diagnosed between 2005 and 2015 at a single medical center.

Of the 201 patients with FL, 39.3% were non-Hispanic White, 19.4% were non-Hispanic Black, and 41.3% were Hispanic. Distribution was similar in patients with CLL.

After they adjusted for International Prognostic Index factors, sex, and chemotherapy, the researchers found that Hispanics with FL had significantly lower all-cause mortality compared with non-Hispanic Whites (hazard ratio [HR] = 0.22; 95% CI, 0.08 to 0.63). There was no significant differences in mortality between non-Hispanic Black patients and non-Hispanic White patients.

The researchers also ran a sensitivity analysis comparing receipt of chemotherapy by race/ethnicity. In an adjusted model, non-Hispanic Black patients with FL, but not Hispanics, were less likely to receive chemotherapy compared with non-Hispanic White patients. Hispanic patients had improved event-free survival compared with non-Hispanic White patients (HR = 0.44; 95% CI, 0.24 to 2.23).

“Overall, these findings contribute key insights into our understanding of racial and ethnic differences in B-cell lymphoma survival,” the researchers wrote. “While more research is needed on genetic differences in disease susceptibility and prognosis, data suggest that genetic variants associated with disease risk may vary by NHL subtype and race/ethnicity.”